Spyre Therapeutics (SYRE) Other Accumulated Expenses (2015 - 2026)
Spyre Therapeutics posted quarterly Other Accumulated Expenses of $165000.0 for Q1 2026, down 55.53% year-on-year from $371000.0 in Q1 2025, and down 7.82% on a QoQ basis from $179000.0 in Q4 2025.
Spyre Therapeutics (SYRE) has 12 years of Other Accumulated Expenses data on file, last reported at $165000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Accumulated Expenses fell 55.53% year-over-year to $165000.0; the trailing twelve-month figure through Mar 2026 stood at $165000.0 (down 55.53% YoY), and the FY2025 full-year result was $179000.0, down 64.27% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $165000.0, down from $179000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $726000.0 in Q1 2022 and bottomed at $165000.0 in Q1 2026.
- The 5-year median for Other Accumulated Expenses is $362000.0 (2022), against an average of $361400.0.
- The widest annual swing landed in 2022, when Other Accumulated Expenses jumped 97.82%; it then sank 67.68% in 2025.
- A 5-year view of Other Accumulated Expenses shows it stood at $330000.0 in 2022, then surged by 47.88% to $488000.0 in 2023, then rose by 2.66% to $501000.0 in 2024, then sank by 64.27% to $179000.0 in 2025, then fell by 7.82% to $165000.0 in 2026.
- The last three Other Accumulated Expenses figures came in at $165000.0 (Q1 2026), $179000.0 (Q4 2025), and $170000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 165,000.00 |
| Dec 31, 2025 | 179,000.00 |
| Sep 30, 2025 | 170,000.00 |
| Jun 30, 2025 | 242,000.00 |
| Mar 31, 2025 | 371,000.00 |
| Dec 31, 2024 | 501,000.00 |
| Sep 30, 2024 | 526,000.00 |
| Jun 30, 2024 | 235,000.00 |
| Dec 31, 2023 | 488,000.00 |
| Jun 30, 2023 | 386,000.00 |
| Mar 31, 2023 | 279,000.00 |
| Dec 31, 2022 | 330,000.00 |
| Sep 30, 2022 | 362,000.00 |
| Jun 30, 2022 | 461,000.00 |
| Mar 31, 2022 | 726,000.00 |
| Dec 31, 2021 | 783,000.00 |
| Sep 30, 2021 | 960,000.00 |
| Jun 30, 2021 | 1.13 Mn |
| Mar 31, 2021 | 367,000.00 |
| Dec 31, 2020 | 464,000.00 |
| Sep 30, 2020 | 639,000.00 |
| Jun 30, 2020 | 607,000.00 |
| Mar 31, 2020 | 714,000.00 |
| Dec 31, 2019 | 469,000.00 |
| Sep 30, 2019 | 110,000.00 |
| Jun 30, 2019 | 94,000.00 |
| Mar 31, 2019 | 125,000.00 |
| Dec 31, 2018 | 133,000.00 |
| Sep 30, 2018 | 88,000.00 |
| Jun 30, 2018 | 75,000.00 |
| Mar 31, 2018 | 110,000.00 |
| Dec 31, 2017 | 159,000.00 |
| Sep 30, 2017 | 233,000.00 |
| Jun 30, 2017 | 212,000.00 |
| Mar 31, 2017 | 115,000.00 |
| Dec 31, 2016 | 227,000.00 |
| Sep 30, 2016 | 165,000.00 |
| Jun 30, 2016 | 87,000.00 |
| Mar 31, 2016 | 50,000.00 |
| Dec 31, 2015 | 50,000.00 |